Related Experiment Video
Updated: Sep 2, 2026

High-Throughput Behavioral Aging and Lifespan Assays Using the Lifespan Machine
Published on: January 26, 2024
A cross-species drug-discovery platform to accelerate the identification of lifespan-extending interventions
Kevin Perez1, Lucas Schoenfeldt2, Grace B Phelps3
1EPITERNA, 1066 Épalinges, Switzerland; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Abstract:
We develop an integrated, high-throughput platform to evaluate pharmacological lifespan-extending interventions across five model organisms spanning unicellular to mammalian biology including yeast, nematodes, fruit flies, killifish, and mice. By combining automated imaging, miniaturized assays, and deep-learning-based death detection, we evaluate over 400 compounds across thousands of conditions. In S. cerevisiae, a miniaturized PI/flow cytometry CLS assay enables scalable screening and identifies key assay confounders, while in C. elegans and D. melanogaster, compact imaging platforms coupled to YOLO-based detection provide a no-transfer, high-throughput survival scoring, and capture compound-, diet-, and sex-dependent effects. In killifish, we develop an in-house drug-pellet formulation for standardized oral delivery in large cohorts, and in mice we combine longitudinal lifespan studies with home-cage activity monitoring to assess late-life interventions. Cross-species integration identifies multi-species geroprotectors and reveals convergence on known and novel conserved longevity pathways, illustrating how this scalable framework can prioritize interventions with high translational potential.
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
